Predictive factors for the benefit of triple‐drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma

BACKGROUND: Compared with single‐drug TACE, our previous phase III study demonstrated that triple‐drug transarterial chemoembolization (TACE) prolonged overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC). The aim of this study was to find which patients can benefit fro...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Med
Egile Nagusiak: He, MinKe, Li, Qing, Shen, JingXian, Tan, GuoSheng, Li, QiJiong, Lai, JiaYing, Wei, Wei, Zhang, YaoJun, Zou, RuHai, Chen, MinShan, Guo, RongPing, Shi, Ming
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2019
Gaiak:
Clinical Cancer Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6675716/
https://ncbi.nlm.nih.gov/pubmed/31207163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2355
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak